| Literature DB >> 35216348 |
Ilaria Ottonelli1,2, Riccardo Caraffi2, Giovanni Tosi2, Maria Angela Vandelli2, Jason Thomas Duskey2, Barbara Ruozi2.
Abstract
Tunneling nanotubes (TNTs), discovered in 2004, are thin, long protrusions between cells utilized for intercellular transfer and communication. These newly discovered structures have been demonstrated to play a crucial role in homeostasis, but also in the spreading of diseases, infections, and metastases. Gaining much interest in the medical research field, TNTs have been shown to transport nanomedicines (NMeds) between cells. NMeds have been studied thanks to their advantageous features in terms of reduced toxicity of drugs, enhanced solubility, protection of the payload, prolonged release, and more interestingly, cell-targeted delivery. Nevertheless, their transfer between cells via TNTs makes their true fate unknown. If better understood, TNTs could help control NMed delivery. In fact, TNTs can represent the possibility both to improve the biodistribution of NMeds throughout a diseased tissue by increasing their formation, or to minimize their formation to block the transfer of dangerous material. To date, few studies have investigated the interaction between NMeds and TNTs. In this work, we will explain what TNTs are and how they form and then review what has been published regarding their potential use in nanomedicine research. We will highlight possible future approaches to better exploit TNT intercellular communication in the field of nanomedicine.Entities:
Keywords: drug exchange; nanomedicine; nanoparticles; targeted therapy; therapeutic efficiency; tunneling nanotubes
Mesh:
Substances:
Year: 2022 PMID: 35216348 PMCID: PMC8878036 DOI: 10.3390/ijms23042237
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Graphical representation of NMeds’ customization options and advantages. Reproduced with permission from Salvioni et al. [71] (Cancers; published by MDPI; 2019).
Figure 2SEM images showing TNTs between macrophages emphasizing disparate sites of connectivity (circled) and the presence of a gondola (white arrow). NMeds are pseudo-colored red in the lower central image. Reproduced with permission from Franco et al. [137] (Cancers; published by MDPI; 2020).
Figure 3Type of TNTs in GBM and healthy astrocytes, and exchange of liposomes via TNTs. (A) Type of TNTs formed by GBM cells before and after administration of doxorubicin. (B) Type of TNTs formed by healthy astrocytes before and after administration of doxorubicin. Data are expressed as mean ± SE from three independent experiments. Data were analyzed by two-way ANOVA followed by Sidak’s multiple comparisons test; n.s., not significant; ** p < 0.01 (C) Experimental protocol to study TNT formation in co-cultures using different fluorophores to distinguish cell types. (D) Homotypical vs. heterotypical transfer via TNTs of doxorubicin-loaded liposomes in co-cultures of GBM and healthy astrocytes. U87-MG: GBM cells; NHA: normal human astrocytes; DOX: doxorubicin. N = 3 independent experiments. * p < 0.05; ** p < 0.01; *** p < 0.001 by Student t-test Reproduced with permission from Formicola et al. [149] (Frontiers in Bioengineering and Biotechnology; published by Frontiers; 2019).
Figure 4Representative imaging of TNTs using a combination of transmitted light and fluorescently labelled NMeds by confocal microscope. Reproduced with permission from Sáenz-de-Santa-María et al. [140] (Oncotarget; 2017).